retatrutide triple agonist glp-1 gip glucagon receptor A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Retatrutide Explained: How the Triple

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

A Need for Balanced Solutions The dilemma reflects broader tensions in the US healthcare system: how to ensure patient safety without stifling access to affordable treatments

A long-term Henry reviewer on Trustpilot: 5 years, 3 successful journeys, and total support

Notably, while GLP-1 can potentially affect glucagon secretion via its stimulatory effect on the -cells in normal physiological conditions, GLP-1 also inhibits glucagon release in type 1 diabetes, thus demonstrating that GLP-1 inhibition of glucagon secretion does not fully depend on the -cell secretome [516]

Lorenzo Leggio, an addiction researcher at the National Institutes of Health, who was not involved in the study

Ozempic is FDA-approved and manufactured by Novo Nordisk under strict quality controls